Scotiabank raised the firm’s price target on BioMarin (BMRN) to $80 from $78 and keeps a Sector Perform rating on the shares. The firm is raising its price target on the stock following a Q4 Voxzogo beat and bullish 2025 revenue outlook, the analyst tells investors. Scotiabank, however, maintains its rating due to concerns about the potential competitive threats to the Voxzogo franchise.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin price target raised to $113 from $109 at UBS
- BioMarin Pharmaceutical: Strong Financial Performance and Promising Growth Prospects Warrant Buy Rating
- BioMarin price target raised to $103 from $99 at BofA
- Strong Financial Performance and Positive Outlook for BioMarin Pharmaceutical
- Strong Financial Performance and Strategic Growth Drive Buy Rating for BioMarin Pharmaceutical